Syngene International Ltd
NSE:SYNGENE

Watchlist Manager
Syngene International Ltd Logo
Syngene International Ltd
NSE:SYNGENE
Watchlist
Price: 869.3 INR 2.64% Market Closed
Market Cap: 348.8B INR
Have any thoughts about
Syngene International Ltd?
Write Note

Gross Margin
Syngene International Ltd

73.6%
Current
72%
Average
43.8%
Industry

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
73.6%
=
Gross Profit
25.4B
/
Revenue
34.5B

Gross Margin Across Competitors

Country IN
Market Cap 348.8B INR
Gross Margin
74%
Country US
Market Cap 1.3T USD
Gross Margin
55%
Country US
Market Cap 196.3B USD
Gross Margin
41%
Country US
Market Cap 170.3B USD
Gross Margin
60%
Country KR
Market Cap 66.5T KRW
Gross Margin
50%
Country CH
Market Cap 37.6B CHF
Gross Margin
29%
Country US
Market Cap 38.5B USD
Gross Margin
55%
Country US
Market Cap 36.7B USD
Gross Margin
35%
Country US
Market Cap 26.4B USD
Gross Margin
59%
Country US
Market Cap 23B USD
Gross Margin
35%
Country US
Market Cap 22.3B USD
Gross Margin
64%
No Stocks Found

Syngene International Ltd
Glance View

Market Cap
348.8B INR
Industry
Life Sciences Tools & Services

Syngene International Ltd. operates as a global discovery, development and manufacturing organization providing integrated scientific services to the pharmaceutical, biotechnology, nutrition, animal health, consumer goods and specialty chemical industries. The company is headquartered in Bangalore, Karnataka and currently employs 5,975 full-time employees. The company went IPO on 2015-08-11. The firm is engaged in providing services from early discovery and development to commercial manufacturing for small and large molecules. Its services include drug discovery and development capabilities in medicinal chemistry, biology, in vivo pharmacology, toxicology, custom synthesis, process research and development, current good manufacturing practice (cGMP) manufacturing, formulation and analytical development along with clinical development services. The company offers SynVent, a therapeutic discovery and development platform for executing drug discovery projects, which is designed to provide a range of advance programs through target validation, translational interrogation, therapeutic discovery and preclinical development for both large and small molecules, as well as specialty modalities, such as targeted protein degradation. The company serves clients ranging from multinational corporations to start-ups.

SYNGENE Intrinsic Value
596.03 INR
Overvaluation 31%
Intrinsic Value
Price

See Also

Discover More
What is Gross Margin?

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
73.6%
=
Gross Profit
25.4B
/
Revenue
34.5B
What is the Gross Margin of Syngene International Ltd?

Based on Syngene International Ltd's most recent financial statements, the company has Gross Margin of 73.6%.